Clinical Research Directory
Browse clinical research sites, groups, and studies.
Taldefgrobep Alfa in Adults With Overweight and Obesity
Sponsor: Biohaven Therapeutics Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Official title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-11-24
Completion Date
2026-09
Last Updated
2026-03-20
Healthy Volunteers
No
Conditions
Interventions
Taldefgrobep Alfa
Subcutaneous injection administered once each week
Placebo
Subcutaneous injection (matching placebo) administered once each week
Taldefgrobep Alfa
Subcutaneous injection administered once every 4 weeks
Placebo
Subcutaneous injection (matching placebo) administered once every 4 weeks
Locations (20)
Site-001
Chula Vista, California, United States
Site-014
Montclair, California, United States
Site-011
Sacramento, California, United States
Site-018
Tustin, California, United States
Site-020
Orlando, Florida, United States
Site-008
Palm Springs, Florida, United States
Site-015
St. Petersburg, Florida, United States
Site-007
Chicago, Illinois, United States
Site-016
Indianapolis, Indiana, United States
Site-010
Baton Rouge, Louisiana, United States
Site-009
Metairie, Louisiana, United States
Site-006
City of Saint Peters, Missouri, United States
Site-003
Springfield, Missouri, United States
Site-019
Monroe, North Carolina, United States
Site-002
Fargo, North Dakota, United States
Site-017
North Charleston, South Carolina, United States
Site-005
Austin, Texas, United States
Site-012
McKinney, Texas, United States
Site-013
San Antonio, Texas, United States
Site-004
Arlington, Virginia, United States